Confirmation
purchase | Item
Code | Item Description | Price |
|---|
| R164 | Complete issue - year 2014, vol.32, n°6 - Suppl.86 | 32.00 € |
| R229 | Complete issue - year 2019, vol.37, n°4 - Suppl.119 | 32.00 € |
| CER17644 | Phase 3, 56-week, randomised, double-blind, placebo-controlled study utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis: OA-11 Study | 20.00 € |
| R185 | Complete issue - year 2016, vol.34, n°3 - Suppl.97 | 32.00 € |
| | Subtotal 116.00 € |
|---|
